TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05496283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: denture adhesive
Description: After 1 month of using the complete denture with no denture adhesives, patients fill up satisfaction and quality of life forms and given 1 of 3 types of denture adhesive to use for month to compare satisfaction and quality of life forms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: denture adhesive
Description: After 1 month of using the complete denture with no denture adhesives, patients fill up satisfaction and quality of life forms and given 1 of 3 types of denture adhesive to use for month to compare satisfaction and quality of life forms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: denture adhesive
Description: After 1 month of using the complete denture with no denture adhesives, patients fill up satisfaction and quality of life forms and given 1 of 3 types of denture adhesive to use for month to compare satisfaction and quality of life forms
Study: NCT06315478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 20 MG Oral Tablet
Description: standard triple therapy for 14 days Bid for each drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 500Mg Tab
Description: Quadruple regimen for 14 days Bid for each drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500Mg Tab
Description: Hybrid regimen, PPI and Amoxicillin for first 7 days then adding clarithromycin and metronidazole for the second 7 days
Study: NCT05212701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin
Description: The oral tablets of the investigational product (IP) will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack (it is preferable that reparixin is taken with food).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The oral tablets of masked placebo will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack
Study: NCT05847257

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Letrozole tablets
Description: letrozole 2.5mg twice weekly for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole tablets
Description: letrozole 2.5mg twice weekly for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 table
Description: Coenzyme Q10 400 mg per day for 3 months
Study: NCT06333574

Intervention type: OTHER
Group type: OTHER
Intervention: Family weight self-measurement and remote follow-up management based on wechat.
Description: On the basis of routine outpatient management, patients or their family members were subjected to remote follow-up management based on wechat, and the follow-up time was 6 months. Specific methods: Same as the control group, the information of weight and blood pressure of the patients was registered at the end of dialysis, and the purpose, role and importance of weight management were informed to the patients. On this basis, a special wechat signal is set up to add patients or patients' family members as wechat friends and establish a wechat interaction platform with patients. In the interdialysis period, remind patients to weigh themselves through wechat (the time of each weighing is fixed, preferably consistent with the time of weighing in the hemodialysis center), control the weight gain during the interdialysis period not to exceed 4.5% of dry weight, and inform patients again about the purpose, role and importance of weight management.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine care
Description: The dialysis doctor registered the information of the patient's weight and blood pressure at the end of dialysis, and informed the patient of the purpose, role and importance of weight management.
Study: NCT04711603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR13A9
Description: Intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MR13A9
Description: Intravenous administration
Study: NCT06316739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ganchero intervention
Description: The Ganchero intervention is an HIV, hepatitis C virus (HCV) and overdose prevention intervention for migrant people who inject drugs (PWID) from Puerto Rico who are living in New York City. The intervention has two core components, both centered around the key migrant PWID role of the Ganchero, an individual who provides expert injection services in exchange for money or drugs. First, a sample of Gancheros will be trained in foundational HIV, HCV and overdose risk-reduction knowledge and outreach strategies (over 6 2-hour, in-person, small group sessions facilitated by an Interventionist). Second, during a 4-month outreach period, trained Gancheros will disseminate risk-reduction messages learned in the training, and associated resources (e.g., sterile syringes and other injection equipment, naloxone), to migrant PWID in their neighborhood as they deliver their regular Ganchero services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ganchero intervention
Description: The Ganchero intervention is an HIV, hepatitis C virus (HCV) and overdose prevention intervention for migrant people who inject drugs (PWID) from Puerto Rico who are living in New York City. The intervention has two core components, both centered around the key migrant PWID role of the Ganchero, an individual who provides expert injection services in exchange for money or drugs. First, a sample of Gancheros will be trained in foundational HIV, HCV and overdose risk-reduction knowledge and outreach strategies (over 6 2-hour, in-person, small group sessions facilitated by an Interventionist). Second, during a 4-month outreach period, trained Gancheros will disseminate risk-reduction messages learned in the training, and associated resources (e.g., sterile syringes and other injection equipment, naloxone), to migrant PWID in their neighborhood as they deliver their regular Ganchero services.
Study: NCT04711603

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration
Study: NCT05256693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Oral vancomycin (powder) 125mg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vancomycine placebo (powder) twice a day
Study: NCT06426862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program
Description: Otago exercise program~Strengthening Exercise Knee extensor, Hip adductors, heel and toe raising~Balance exercise Sit to stand, Knee bending, one leg standing, tandem stance, side walk, walk and turn around, tandem walk, backward walk, heel and toe walk, stair climbing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Routine physiotherapy like strengthening, stretching, postural awareness, gait and balance training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Routine physiotherapy like strengthening, stretching, postural awareness, gait and balance training.
Study: NCT05164640

Intervention type: OTHER
Group type: OTHER
Intervention: not required
Description: This a multicenter, prospective, non-randomized, single-arm, open label clinical study. This design doesn't include control vs intervention arms
Study: NCT05220462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: As per Remimazolam arm
Study: NCT04718714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: loading dose intravenous infusion of 0.2 mg/kg over 10 minutes followed by a maintenance dose of 0.02 -0.2 mg /kg/hr. over 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: loading dose intravenous infusion of one mg/kg over 15 minutes followed by a maintenance dose of 20-80 microgram/kg/min. over 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: loading dose of dexmedetomidine of one µg/kg over 10 minutes followed by maintenance dose of 0.2 -1.5 µg/kg/hr. over 24 hours.
Study: NCT05950269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walking aid
Description: A physiotherapist will identify the mobility needs and will indicate the most appropriate walking aid (cane or walker).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walking aid
Description: A physiotherapist will identify the mobility needs and will indicate the most appropriate walking aid (cane or walker).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Telemonitoring will occur every two weeks for three months after the emergency department discharge, through video call (about 15 minutes). On these opportunities, the importance of using mobile devices and the guidance on safe gait will be reinforced.

Intervention type: OTHER
Group type: OTHER
Intervention: Guidance on safe walking and risk of falling
Description: Participants will receive verbal guidance and printed material with guidance on safe walking and fall prevention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guidance on safe walking and risk of falling
Description: Participants will receive verbal guidance and printed material with guidance on safe walking and fall prevention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guidance on safe walking and risk of falling
Description: Participants will receive verbal guidance and printed material with guidance on safe walking and fall prevention.
Study: NCT05116865

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HH-120 Dose 2
Description: Dose level 2 of HH-120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HH-120 Dose 2
Description: Dose level 2 of HH-120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HH-120 Dose 3
Description: Dose level 3 of HH-120
Study: NCT05220462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: As per Midazolam arm
Study: NCT06471244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Finger tapping
Description: The volunteer is tapping with his/her right hand index finger.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Median nerve stimulation
Description: Electrical pulses are applied at the wrist to the median nerve.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech processing
Description: German sentences are played to the volunteers and the volunteers have to fulfill a semantic task.
Study: NCT04938115

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7 CART
Description: Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
Study: NCT05610384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Injectable Solution
Description: ketorolac 30 mg (diluted in 200 mL normal saline) intravenously over 5 minutes before induction of anesthesia then every 8 hours postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 800 mg
Description: ibuprofen 800 mg intravenously (Diluted in 200 mL of normal saline) over 5 minutes before induction of anesthesia then every 8 hours postoperatively.
Study: NCT05093530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neumifil
Description: Neumifil contains the active ingredient HEX17, a multivalent, glycan-targeting carbohydrate binding module (CBM). HEX17 CBM is suspended in an aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.
Study: NCT04752891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AOM diagnosis with app
Description: the diagnosis made by a senior physician using a traditional otoscope. the diagnosis made by the junior physician using an otoendoscope fixed on a connected smartphone

Intervention type: OTHER
Group type: OTHER
Intervention: AOM diagnosis without app
Description: the diagnosis made by a senior physician and by the junior physician, using a traditional otoscope
Study: NCT05713734

Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombin generation
Description: Measurement of thrombin generation by ST Genesia

Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombin generation
Description: Measurement of thrombin generation by ST Genesia

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibrinolysis
Description: Measurement of fibrinolysis by Lysis Timer

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibrinolysis
Description: Measurement of fibrinolysis by Lysis Timer

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibrin clot structure
Description: Measurement of fibrin polymerisation and permeability

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibrin clot structure
Description: Measurement of fibrin polymerisation and permeability

Intervention type: DIAGNOSTIC_TEST
Intervention: Coated platelets
Description: Measurement of coated platelets by flow cytometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Coated platelets
Description: Measurement of coated platelets by flow cytometry
Study: NCT05756452

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anamnesis and clinical evaluation
Description: All partecipants will undergo a global echocardiographic evaluation, a 24-hour ECG Holter recording to assess HRV and blood samples collection for neurotransmitter measurements, platelet activation and reactivity evaluation and inflammatory profile assessment by proteomics analysis, inflammasome activity evaluation, NLRP3, pro-IL-18 and pro-IL-1β expression level by qPCR and epigenetic analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anamnesis and clinical evaluation
Description: All partecipants will undergo a global echocardiographic evaluation, a 24-hour ECG Holter recording to assess HRV and blood samples collection for neurotransmitter measurements, platelet activation and reactivity evaluation and inflammatory profile assessment by proteomics analysis, inflammasome activity evaluation, NLRP3, pro-IL-18 and pro-IL-1β expression level by qPCR and epigenetic analysis.
Study: NCT05206864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Food: SBD111
Description: One capsule administered twice daily with morning and evening meals for 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule administered twice daily with morning and evening meals for 28 days
Study: NCT06123572

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-Ageing and Skin Brightening Gel
Description: Anti-Ageing and Skin Brightening Gel.
Study: NCT05116865

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HH-120 Dose 3
Description: Dose level 3 of HH-120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match
Study: NCT04772885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-474/Placebo
Description: KT-474 or matching placebo oral tablet(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-474/Placebo
Description: KT-474 or matching placebo oral tablet(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-474/Placebo
Description: KT-474 or matching placebo oral tablet(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-474/Placebo
Description: KT-474 or matching placebo oral tablet(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-474
Description: KT-474 oral tablet(s)
Study: NCT05871931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tidal Model-based psychiatric nursing approach
Description: 8 meetings in 2 month
Study: NCT05947773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Learning to walk with a robot
Description: The patients completed a 1-hour learning to walk program using a soft exoskeleton. The protocol includes several difficult parts of the walk. (Walking protocol)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking group
Description: The walking protocol was performed without robotic assistance for 1 hour every day for 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: The control group performed the physiotherapy treatment for 3 weeks.
Study: NCT05677737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Educational program; It will be applied to the individuals in the experimental group for an average of 40 minutes in a time period they are suitable through the online platform prepared for the individuals in the experimental group in a three-month period. The literature will be scanned and appropriate educational materials will be created, and videos will be used to support education.~Educational program During the first interview, the individuals in the experimental group will be introduced to the online platform, their entrance will be provided, they will be informed about how to follow the trainings, and sample applications will be made.~Six main topics will be covered in the training program and will be completed every two weeks in three months.
Study: NCT05512806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462 orally.
Study: NCT06503406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SupraSDRM®
Description: SupraSDRM® Bidegradable Matrix Wound Dressing is a tri-polymber, Biodegrable dermal covering manufactured by PolyMedics Innovations, GmbH.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovoSorb® BTM
Description: NovoSorb® BTM absorbable synthetic wound dressing, PolyNovo Biomaterials, K172140
Study: NCT05958316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Symptom Capture Tool (C-SCAT) Intervention
Description: The C-SCAT includes the 32 symptoms from the Memorial Symptom Assessment Scale (MSAS). Users select symptoms they have experienced over the past week, rate each symptom's severity and distress, and name a perceived cause. They then identify temporal and causal relationships between symptoms using lines and arrows, designate groups, i.e., clusters of symptoms, and give a name to each cluster. They are asked the reason for a symptom's designation as a priority symptom and what they do to alleviate that symptom. Next, they are asked to designate a priority cluster and finally, to confirm whether the image accurately reflects their symptom experience. Then, at the clinic visit, the AYA shares the visual image with the HCP, and more importantly, their priority symptoms, which can facilitate the symptom discussion. The C-SCAT intervention group will complete the C-SCAT prior to each of three encounters with their health care providers (HCPs).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Control
Description: Usual care is defined as the usual approach to assessing symptoms during the HCP encounter. To provide attentional control to the usual care control group and prevent disproportionate attrition from that group, study staff will contact participants three times during the intervention period (approximately 3 months) when they are in for a scheduled clinic visit and communicate the following: 1) express appreciation for ongoing study participation; 2) ask how everything is going with their treatment; 3) ask if anything has changed with their treatment plan since the last study visit; and 4) confirm continued participation in the study.
Study: NCT05839652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Hydrochloride
Description: Determine best drug and dose to increase and stabilize SBP during orthostatic tilt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Hydrochloride
Description: Determine best drug and dose to increase and stabilize SBP during orthostatic tilt
Study: NCT06429215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-component Intervention (MC-I): VR Cognitive training and Psychoeducation on health and lifestyle
Description: In a period of 5 consecutive weeks, participants will receive:~* an interactive immersive virtual reality cognitive training for 30 minutes, 3 days per week. It consists in different tasks implemented in virtual real-like scenarios of daily living situations that target the following cognitive processes: long-term associative memory, relational binding, spatial pattern separation and pattern completion;~* an interactive immersive virtual reality health and lifestyle education program for 30 minutes, 1 day per week. It consists in 360° videos aimed at advancing awareness and knowledge of the various health conditions associated with an increased risk of cognitive decline and dementia and helping participants to develop a healthier lifestyle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-only intervention (CO-I): VR Cognitive training (+ Psychoeducation active control)
Description: In a period of 5 consecutive weeks, participants will receive:~* the interactive immersive virtual reality cognitive training as described in the MC-I condition, for about 30 minutes, 3 days per week;~* an active control of the immersive virtual reality psychoeducation program for 30 minutes, 1 day per week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active control intervention (AC-I): VR Cognitive active control + Psychoeducation active control
Description: In a period of 5 consecutive weeks, participants will receive:~* an active control of the immersive virtual reality cognitive training (participants will be requested to virtually carry out daily actions, in the same setting as those performed in cognitive immersive VR training, but they will follow prearranged instructions requiring very low cognitive demands) for about 30 minutes, 3 days per week;~* an active control of the immersive virtual reality psychoeducation program for about 30 minutes, 1 day per week.